Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice

Molecular Therapy

Volumn 17, Issue 5, 2009, Pages 864-871

  Wu, Bo ^a   Li, Yongfu ^b   Morcos, Paul A ^b   Doran, Timothy J ^a   Lu, Peijuan ^a   Lu, Qi Long ^a  

^a Neuromuscular/ALS Center   (United States)

^b Gene Tools LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CREATINE KINASE; DYSTROPHIN; OCTAGUANIDINE MORPHOLINO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG CONJUGATION; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART MUSCLE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SINGLE DRUG DOSE; SKELETAL MUSCLE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CREATINE KINASE; DYSTROPHIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED MDX; MORPHOLINES; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MYOCARDIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

MUS;

EID: 67349137953     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.38     Document Type: Article

References (29)

1. Blow, N (2007). Small RNAs: Delivering the future. Nature 450 1117-1120.
2. Kumar, P, Wu, H, McBride, JL, Jung, KE, Kim, MH, Davidson, BL et al. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43.
3. Sherratt, TG, Vulliamy, T, Dubowitz, V, Sewry, CA and Strong, PN (1993). Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. Am J Hum Genet 53: 1007-1015.
4. Dunckley, MG, Manoharan, M, Villiet, P, Eperon, IC and Dickson, G (1998). Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 7 1083-1090.
5. Mann, CJ, Honeyman, K, Cheng, AJ, Ly, T, Lloyd, F, Fletcher, S et al. (2001). Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 98: 42-47.
6. Lu, QL, Mann, CJ, Lou, F, Bou-Gharios, G, Morris, GE, Xue, SA et al. (2003). Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9: 1009-1014.
7. Dickson, G, Hill, V and Graham, IR (2002). Screening for antisense modulation of dystrophin pre-mRNA splicing. Neuromuscul Disord 12 (suppl. 1): S67-S70.
8. Aartsma-Rus, A, Bremmer-Bout, M, Janson, AA, den Dunnen, JT, van Ommen, GJ and van Deutekom, JC (2002). Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 12 (suppl. 1): S71-S77.
9. England, SB, Nicholson, LV, Johnson, MA, Forrest, SM, Love, DR, Zubrzycka-Gaarn, EE et al. (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343 180-182.
10. Sakamoto, M, Yuasa, K, Yoshimura, M, Yokota, T, Ikemoto, T, Suzuki, M et al. (2002). Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 293: 1265-1272.
11. Winnard, AV, Klein, CJ, Coovert, DD, Prior, T, Papp, A, Snyder, P et al. (1993). Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy. Hum Mol Genet 2 737-744.
12. Mirabella, M, Galluzzi, G, Manfredi, G, Bertini, E, Ricci, E, De Leo, R et al. (1998). Giant dystrophin deletion associated with congenital cataract and mild muscular dystrophy. Neurology 51 592-595.
13. Lu, QL, Morris, GE, Wilton, SD, Ly, T, Artem'yeva, OV, Strong, P et al. (2000). Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol 148: 985-996.
14. van Deutekom, JC, Janson, AA, Ginjaar, IB, Frankhuizen, WS, Aartsma-Rus, A, Bremmer-Bout, M et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357: 2677-2686.
15. Alter, J, Lou, F, Rabinowitz, A, Yin, H, Rosenfeld, J, Wilton, SD et al. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12: 175-177.
16. Eagle, M, Bourke, J, Bullock, R, Gibson, M, Mehta, J, Giddings, D et al. (2007). Managing Duchenne muscular dystrophy-the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 17: 470-475.
17. Wagner, KR, Lechtzin, N and Judge, DP (2007). Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta 1772: 229-237.
18. Fletcher, S, Honeyman, K, Fall, AM, Harding, PL, Johnsen, RD, Steinhaus, JP et al. (2007). Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 15: 587-1592.
19. Wu, B, Moulton, HM, Iversen, PL, Jiang, J, Li, J, Spurney, CF et al. (2008). Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 105: 14814-14819.
20. Yin, H, Moulton, HM, Seow, Y, Boyd, C, Boutilier, J, Iverson, P et al. (2008). Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17: 3909-3918.
21. Jearawiriyapaisarn, N, Moulton, HM, Buckley, B, Roberts, J, Sazani, P, Fucharoen, S et al. (2008). Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16: 1624-1629.
22. Futaki, S, Nakase, I, Suzuki, T, Youjun, Z and Sugiura, Y (2002). Translocation of branched-chain arginine peptides through cell membranes: Flexibility in the spatial disposition of positive charges in membrane-permeable peptides. Biochemistry 41: 7925-7930.
23. Hoffman, EP, Morgan, JE, Watkins, SC and Partridge, TA (1990). Somatic reversion/suppression of the mouse mdx phenotype in vivo. J Neurol Sci 99: 9-25.
24. Sicinski, P, Geng, Y, Ryder-Cook, AS, Barnard, EA, Darlison, MG and Barnard, PJ (1989). The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 244: 1578-1580.
25. Lu, QL, Rabinowitz, A, Chen, YC, Yokota, T, Yin, H, Alter, J et al. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102: 198-203.
26. Kurreck, J (2003). Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270: 1628-1644.
27. Summerton, J and Weller, D (1997). Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7: 187-195.
28. Abes, S, Moulton, HM, Clair, P, Prevot, P, Youngblood, DS, Wu, RP et al. (2006). Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 116: 304-313.
29. Li, YF and Morcos, PA (2008). Design and synthesis of the dendritic molecular transporter that achieves efficient in vivo delivery of morpholino antisense oligo. Bioconjug Chem 19: 1464-1470.